Curated News:

NEJM

Add to Favorites Subscribe Share
fbshare-NEJM

Showing results

110 of 311
Embargo will expire:
19-May-2019 3:45 PM EDT
Released to reporters:
16-May-2019 5:05 PM EDT

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 19-May-2019 3:45 PM EDT

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

mmc-logo.gif

Article ID: 713047

تظهر الدراسة أن الدواء يقلل من خطر الانتكاس لمرض التهاب النخاع والعصب البصري

Mayo Clinic

قلّل دواء إيكوليزوماب "eculizumab"، وهو عبارة عن جسم مضاد اصطناعي يثبّط الاستجابة الالتهابية، بشكل كبير من مخاطر الانتكاس لمرض اضطراب طيف التهاب النخاع والعصب البصري (NMOSD). قد يسبب هذا الاضطراب الالتهابي المناعي الذاتي الذي يُعدّ مرضًا نادرًا لكنه حاد الإصابة بالعمى والشلل والموت. قدّم الباحثون والمتعانون الدوليون لدى Mayo Clinic النتائج التي توصلوا إليها في دراسة عشوائية مزدوجة التعمية باستخدام دواء وهمي، والتي نشرت في المجلة الطبية New England Journal of Medicine . وسيتم تقديم عملهم أيضًا في جلسة منصة العلوم الناشئة، وهي جزء من الاجتماع السنوي الواحد والسبعين للأكاديمية الأمريكية لعلم الأعصاب المنعقد في الفترة ما بين 4 إلى 10 مايو/أيّار في فيلادلفيا.

Released:
16-May-2019 3:05 PM EDT
mmc-logo.gif

Article ID: 713050

Estudo mostra que droga reduz risco de recaída da neuromielite óptica

Mayo Clinic

O medicamento eculizumab, um anticorpo sintético que inibe a resposta inflamatória, reduziu significativamente o risco de recaída do doenças do espectro neuromielite óptica (NMOSD). Esse distúrbio inflamatório autoimune raro, mas grave, pode causar cegueira, paralisia e morte.

Released:
16-May-2019 3:05 PM EDT
JHSPH-new-logo.jpg

Article ID: 712621

How Nipah Virus Spreads From Person to Person: Lessons From 14 Years of Investigations

Johns Hopkins Bloomberg School of Public Health

The deadly Nipah virus, which is carried by bats and occasionally infects people, is more likely to be transmitted from person to person when the infected patient is older, male and/or has breathing difficulties, according to a study co-led by scientists at the Johns Hopkins Bloomberg School of Public Health.

Released:
9-May-2019 8:45 AM EDT
mmc-logo.gif

Article ID: 712333

Study shows drug reduces risk of relapse with neuromyelitis optica

Mayo Clinic

The drug eculizumab, a synthetic antibody that inhibits the inflammatory response, significantly reduced the risk of relapse with neuromyelitis optica spectrum disorder (NMOSD). Mayo Clinic researchers and international collaborators published their findings in the New England Journal of Medicine.

Released:
3-May-2019 12:05 AM EDT
ASA Logo RGB.jpg

Article ID: 712112

ASA Applauds CDC Acknowledgement of Misinterpretation of Opioid Prescribing Guideline

American Society of Anesthesiologists (ASA)

The American Society of Anesthesiologists (ASA) is pleased with the Centers for Disease Control and Prevention (CDC) article published in the New England Journal of Medicine acknowledging problems with the agency’s Guideline for Prescribing Opioids for Chronic Pain. ASA has been a longtime advocate for the Guideline and was involved in its review and development in 2016.

Released:
30-Apr-2019 10:25 AM EDT
dana-farber-logo.jpg
  • Embargo expired:
    24-Apr-2019 5:00 PM EDT

Article ID: 711770

Targeted therapy proves effective against aggressive rare blood cancer

Dana-Farber Cancer Institute

Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease

Released:
23-Apr-2019 11:05 AM EDT
Pemmaraju.jpg
  • Embargo expired:
    24-Apr-2019 5:00 PM EDT

Article ID: 711831

Study of Tagraxofusp Reports 90 Percent Response Rate for Deadly Blood Cancer with No Prior Available Therapies

University of Texas M. D. Anderson Cancer Center

An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD Anderson Cancer Center, reports that treatment with the drug tagraxofusp resulted in high response rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but highly aggressive – and often fatal bone marrow and blood disorder – for which there are no existing approved therapies.

Released:
24-Apr-2019 9:00 AM EDT
spong-thumb.jpg

Article ID: 710770

More clinical studies needed for lactating women

UT Southwestern Medical Center

While an estimated 83 percent of new mothers in the United States breastfeed at some time during the postpartum period, and more than half of women breastfeeding take one or more medications, most clinical studies exclude lactating women so the effects of those medications on mom and baby aren’t directly known.

Released:
4-Apr-2019 10:05 AM EDT
hms-logo.gif
  • Embargo expired:
    3-Apr-2019 5:00 PM EDT

Article ID: 710576

In New Report, Scientists Outline the Promises and Pitfalls of Machine Learning in Medicine

Harvard Medical School

A New England Journal of Medicine report penned by scientists at Harvard Med and Google offers a blueprint for integrating machine learning into the practice of medicine as way to optimize clinical care.

Released:
1-Apr-2019 3:50 PM EDT

Showing results

110 of 311

Chat now!